Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Oncotarget | 2016

Radiotherapy is commonly used to treat a variety of solid tumors but improvements in the therapeutic ratio are sorely needed. The aim of this study was to assess the Chk1 kinase inhibitor, MK-8776, for its ability to radiosensitize human tumor cells. Cells derived from NSCLC and HNSCC cancers were tested for radiosensitization by MK-8776. The ability of MK-8776 to abrogate the radiation-induced G2 block was determined using flow cytometry. Effects on repair of radiation-induced DNA double strand breaks (DSBs) were determined on the basis of rad51, γ-H2AX and 53BP1 foci. Clonogenic survival analyses indicated that MK-8776 radiosensitized p53-defective tumor cells but not lines with wild-type p53. Abrogation of the G2 block was evident in both p53-defective cells and p53 wild-type lines indicating no correlation with radiosensitization. However, only p53-defective cells entered mitosis harboring unrepaired DSBs. MK-8776 appeared to inhibit repair of radiation-induced DSBs at early times after irradiation. A comparison of MK-8776 to the wee1 inhibitor, MK-1775, suggested both similarities and differences in their activities. In conclusion, MK-8776 radiosensitizes tumor cells by mechanisms that include abrogation of the G2 block and inhibition of DSB repair. Our findings support the clinical evaluation of MK-8776 in combination with radiation.

Pubmed ID: 27690219 RIS Download

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: P30 CA016672
  • Agency: NCI NIH HHS, United States
    Id: R01 CA168485

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


FaDu (cell line)

RRID:CVCL_1218

Cell line FaDu is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MRC-9 (cell line)

RRID:CVCL_2629

Cell line MRC-9 is a Finite cell line with a species of origin Homo sapiens

View all literature mentions

NCI-H460 (cell line)

RRID:CVCL_0459

Cell line NCI-H460 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Calu-6 (cell line)

RRID:CVCL_0236

Cell line Calu-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H1299 (cell line)

RRID:CVCL_0060

Cell line NCI-H1299 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

A-549 (cell line)

RRID:CVCL_0023

Cell line A-549 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions